Articles Vol. 66 No. 5 20/09/2025

5. HIGH-SENSITIVITY TROPONIN I IN TYPE 2 DIABETES MELLITUS: ASSOCIATIONS WITH BLOOD PRESSURE, ANEMIA AND RENAL FUNCTION

Do Anh Duong1,2, Quoc Ky Duyen1,2
1 Faculty of Medical Laboratory Technology, Nguyen Tat Thanh University
2 Khoa Kỹ thuật Xét nghiệm Y học, Trường Đại học Nguyễn Tất Thành
Corresponding author: qkduyen@ntt.edu.vn
DOI: 10.52163/yhc.v66i5.3089
21 Views
9 Downloads
Keywords
High-sensitivity Troponin I, type 2 diabetes, hypertension, anemia, renal function.
Abstract

Objective: Analysis of the relationship between high-sensitivity Troponin I and some cardiovascular risk factors such as hypertension, anemia and renal dysfunction.

Methods: A case-control study was conducted on 372 hospitalized patients, divided into type 2 diabetes and non- type 2 diabetes groups.

Results: Results showed that high-sensitivity Troponin I levels were significantly higher in type 2 diabetes patients compared to non-diabetics (254.1 ± 745.7 and 95.9 ± 384.8 pg/mL, p < 0.001). High-sensitivity Troponin I was also elevated in patients with anemia and hypertension. A weak but statistically significant inverse correlation was found between hemoglobin and high-sensitivity Troponin I levels (r = -0.1, p = 0.05).

Conclusions: High-sensitivity Troponin I tends to be elevated in type 2 diabetes patients with concomitant hypertension, anemia, and renal dysfunction, although the degree of association varies among factors. The increase in high-sensitivity Troponin I in type 2 diabetes patients even in the absence of obvious clinical symptoms suggests a potential role for high-sensitivity Troponin I in assessing early cardiovascular damage in diabetic patients.

References
[1]
American Diabetes Association. Standards of medical care in diabetes-2023. Diabetes Care, 2023, 46 (Suppl 1): S1-S232. Google Scholar
[2]
Ford I, Shah A.S, Zhang R et al. High-sensitivity cardiac Troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol, 2016, 68 (25): 2719-28. Google Scholar
[3]
Rawshani A, Rawshani A, Franzén S et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2018, 379 (7): 633-44. Google Scholar
[4]
Zeller T, Ojeda F, Brunner F, Peitsmeyer P, Münzel T, Binder H et al. High-sensitivity cardiac Troponin I in the general population - defining reference populations for the determination of the 99th percentile in the Gutenberg Health Study. Clin Chem Lab Med, 2015, 53 (5): 699-706. doi: 10.1515/cclm-2014-0619. Google Scholar
[5]
Yiu K.H, Lau K.K, Zhao C.T et al. Predictive value of high-sensitivity Troponin I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 2014, 13: 63. doi: 10.1186/1475-2840-13-63 Google Scholar
[6]
Shahid M.H, Ali N, Ratnala M et al. Prognostic value of high-sensitivity Troponin in predicting long-term cardiovascular outcomes in patients with type 2 diabetes: a systematic review. Cureus, 2025, 17 (5): e83925. doi: 10.7759/cureus.83925 Google Scholar
[7]
Cavender M.A, White W.B, Jarolim P et al. Serial measurement of high-sensitivity Troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation, 2017, 135 (20): 1911-21. doi: 10.1161/CIRCULATIONAHA.116.024632 Google Scholar
[8]
Ralli S, Horwich T.B, Fonarow G.C. Relationship between anemia, cardiac Troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J, 2005, 150 (6): 1220-7. doi: 10.1016/j.ahj.2005.01.049 Google Scholar
[9]
Karar T, Elfaki E.M, Qureshi S. Determination of the serum levels of Troponin I and creatinine among Sudanese type 2 diabetes mellitus patients. J Nat Sci Biol Med, 2015, 6 (Suppl 1): S80-4. doi: 10.4103/0976-9668.166092 Google Scholar